Esketamine - Wikipedia
SPRAVATO®▽ (Esketamine) Nasal Spray Approved in Europe for Adults with Treatment-Resistant Major Depressive Disorder | Business Wire
esketamine
Esketamine is approved in Europe for treating resistant major depressive disorder
NHS spending watchdog rejects ketamine nasal spray for depression as psychiatrists accuse NICE of 'discriminating' against the mentally ill - after the EU approved a £1,000-a-week drug - US Today News
J&J builds case for Spravato in tough-to-treat depression
Esketamine for treatment resistant depression: a trick of smoke and mirrors? | Epidemiology and Psychiatric Sciences | Cambridge Core
Esketamine for Treatment-Resistant Depression - CADTH Issues in Emerging Health Technologies - NCBI Bookshelf
Spravato, INN-esketamine
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program | SpringerLink
EMA Tracker: HCPs Anticipating 2020 Approval | Knowledge | CREATION.co
Janssen's esketamine nasal spray approved in the EU - Pharmaceutical Technology
Seven new meds recommended for EU approval, including first Ebola vacc
Ketamine-like drug for depression gets UK licence | Medical research | The Guardian
EMA Panel Backs Esketamine Nasal Spray for Resistant Depression
PDF) Case report: Effectiveness of brexpiprazole and esketamine/ketamine combination: A novel therapeutic strategy in five cases of treatment-resistant depression
Esketamine nasal spray for treatment‐resistant depression - Chaplin - 2020 - Prescriber - Wiley Online Library
EMA Tracker: HCPs Anticipating 2020 Approval | Knowledge | CREATION.co
Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA - ScienceDirect
Characteristics of the three short-term esketamine efficacy trials... | Download Scientific Diagram
Full article: Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme
CHMP selects drugs for EU market approval - European Biotechnology
